Technology Review - Published By MIT
Advertisement
TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.
I'm a paid subscriber please
log me in
I want to purchase this article for
only $1.99
(requires login)
I want to purchase five articles for
only $7.99
(requires login)
I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

July 2001

Antisense Makes Sense

But it's taken Paul Zamecnik's idea a long, long time.

By Technology Review

n the early days of bio-tech, all eyes focused on the techniques of "recombinant DNA": splicing together bits of DNA from different sources. These 30-year-old genetic engineering methods are now the basis of a multibillion-dollar market for protein-based drugs. Today, another class of biotech drugs is emerging from the lab, but the technology for these "antisense therapies" isn't new-it dates back to 1978, just a few years after the first gene-splicing experi-ments. A few persistent researchers have shepherded it down a long, bumpy road.

Select from the choices above
to read the entire article.


Log In

Forgot your password?     Register »
Advertisement

Videos

Microsoft's Many Multitouch Mice
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2009 Technology Review. All Rights Reserved.